Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allovir Inc ALVR

Healthcare Biotechnology
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life... see more

Recent & Breaking News (NDAQ:ALVR)

ALLOVIR INVESTOR ALERT: Kirby McInerney LLP Alerts AlloVir, Inc. (ALVR) Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit

Newsfile March 8, 2024

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Newsfile March 8, 2024

AlloVir, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

Accesswire March 8, 2024

March 19, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ALVR

Accesswire March 8, 2024

UPCOMING ALVR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit!

Accesswire March 8, 2024

ALVR LAWSUIT ALERT: Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Accesswire March 8, 2024

Shareholders of AlloVir, Inc. Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

Accesswire March 8, 2024

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Accesswire March 8, 2024

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Newsfile March 7, 2024

Investors in AlloVir, Inc. Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

Accesswire March 7, 2024

AlloVir, Inc. Class Action: Levi & Korsinsky Reminds AlloVir Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - ALVR

Accesswire March 7, 2024

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. Lawsuit - ALVR

PR Newswire March 7, 2024

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. Lawsuit - ALVR

Accesswire March 7, 2024

Contact Levi & Korsinsky by March 19, 2024 Deadline to Join Class Action Against AlloVir, Inc.(ALVR)

Accesswire March 7, 2024

AlloVir, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

Accesswire March 7, 2024

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Accesswire March 7, 2024

Levi & Korsinsky Reminds AlloVir Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - ALVR

Accesswire March 6, 2024

AlloVir Shareholder Notice

Newsfile March 6, 2024

Shareholders that lost money on AlloVir, Inc.(ALVR) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Accesswire March 6, 2024

MARCH 19 DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Accesswire March 6, 2024